Janux Gross Profit from 2010 to 2025

JANX Stock

USD 32.60 0.09 0.28%

Janux Therapeutics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit will likely drop to about 4 M in 2025. Gross Profit is the profit Janux Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

7 M

Current Value

4 M

Quarterly Volatility

3 M

Credit Downgrade

Yuan Drop

Covid

Check Janux Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Janux Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 15.1 M, Depreciation And Amortization of 2.4 M or Interest Expense of 4.9 M, as well as many indicators such as Price To Sales Ratio of 127, Dividend Yield of 0.0 or PTB Ratio of 1.3. Janux financial statements analysis is a perfect complement when working with Janux Therapeutics Valuation or Volatility modules.

Check out the analysis of Janux Therapeutics Correlation against competitors.

For more information on how to buy Janux Stock please use our How to Invest in Janux Therapeutics guide.

Latest Janux Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Janux Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Janux Therapeutics minus its cost of goods sold. It is profit before Janux Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Janux Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Janux Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (46.77 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Janux Gross Profit Regression Statistics

	Arithmetic Mean	1,836,872
	Coefficient Of Variation	164.49
	Mean Deviation	2,534,825
	Median	(6,000)
	Standard Deviation	3,021,437
	Sample Variance	9.1T
	Range	8.6M
	R-Value	0.75
	Mean Square Error	4.3T
	R-Squared	0.56
	Significance	0.0009
	Slope	474,801
	Total Sum of Squares	136.9T

Janux Gross Profit History

	2025	4 M
	2024	7 M
	2023	6.1 M
	2022	8.6 M
	2021	3.6 M
	2020	-13 K

Other Fundumenentals of Janux Therapeutics

Gross Profit Margin

Janux Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Capital Surpluse
Total Assets		1.0	0.97	-0.48	-0.89	1.0	0.8	1.0	-0.41	1.0	1.0	1.0	-0.81	1.0	0.87	0.53	0.69
Total Stockholder Equity	1.0		0.97	-0.49	-0.88	1.0	0.77	1.0	-0.41	1.0	1.0	1.0	-0.8	1.0	0.85	0.54	0.68
Net Tangible Assets	0.97	0.97		-0.44	-0.9	0.97	0.76	0.97	-0.59	0.97	0.96	0.97	-0.82	0.96	0.9	0.55	0.72
Net Debt	-0.48	-0.49	-0.44		0.1	-0.47	-0.27	-0.49	-0.19	-0.5	-0.44	-0.5	0.6	-0.44	-0.13	-0.93	0.12
Retained Earnings	-0.89	-0.88	-0.9	0.1		-0.89	-0.86	-0.88	0.62	-0.88	-0.91	-0.88	0.7	-0.91	-0.98	-0.23	-0.81
Accounts Payable	1.0	1.0	0.97	-0.47	-0.89		0.8	1.0	-0.43	1.0	1.0	1.0	-0.83	1.0	0.86	0.51	0.7
Total Liab	0.8	0.77	0.76	-0.27	-0.86	0.8		0.77	-0.43	0.78	0.81	0.78	-0.8	0.81	0.87	0.31	0.72
Net Invested Capital	1.0	1.0	0.97	-0.49	-0.88	1.0	0.77		-0.41	1.0	1.0	1.0	-0.8	1.0	0.85	0.54	0.68
Short Long Term Debt	-0.41	-0.41	-0.59	-0.19	0.62	-0.43	-0.43	-0.41		-0.41	-0.42	-0.41	0.4	-0.42	-0.69	-0.01	-0.8
Total Current Assets	1.0	1.0	0.97	-0.5	-0.88	1.0	0.78	1.0	-0.41		1.0	1.0	-0.82	1.0	0.85	0.55	0.68
Capital Stock	1.0	1.0	0.96	-0.44	-0.91	1.0	0.81	1.0	-0.42	1.0		1.0	-0.79	1.0	0.88	0.49	0.72
Net Working Capital	1.0	1.0	0.97	-0.5	-0.88	1.0	0.78	1.0	-0.41	1.0	1.0		-0.82	1.0	0.85	0.55	0.68
Short Term Debt	-0.81	-0.8	-0.82	0.6	0.7	-0.83	-0.8	-0.8	0.4	-0.82	-0.79	-0.82		-0.79	-0.68	-0.53	-0.51
Common Stock	1.0	1.0	0.96	-0.44	-0.91	1.0	0.81	1.0	-0.42	1.0	1.0	1.0	-0.79		0.88	0.49	0.72
Property Plant Equipment	0.87	0.85	0.9	-0.13	-0.98	0.86	0.87	0.85	-0.69	0.85	0.88	0.85	-0.68	0.88		0.3	0.85
Current Deferred Revenue	0.53	0.54	0.55	-0.93	-0.23	0.51	0.31	0.54	-0.01	0.55	0.49	0.55	-0.53	0.49	0.3		-0.01
Capital Surpluse	0.69	0.68	0.72	0.12	-0.81	0.7	0.72	0.68	-0.8	0.68	0.72	0.68	-0.51	0.72	0.85	-0.01

Click cells to compare fundamentals

About Janux Therapeutics Financial Statements

Janux Therapeutics investors use historical fundamental indicators, such as Janux Therapeutics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Janux Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	7 M	4 M
Gross Profit Margin	0.87	0.97

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for Janux Stock Analysis

When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC